Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Lupin, Norgine, ASKA Pharma - LARVOL DELTA

Rifaximin use in cirrhotic patients with hepatic encephalopathy increases risk of antimicrobial resistance and clostridioides difficile infection (IDDF 2025) - "Rifaximin initiators exhibited a higher one-year incidence of AMR compared to non-users (3.49% vs. 1.83%; hazard ratio [HR], 1.89; 95% confidence intervals [CI], 1.49–2.40), with significantly increased risks of vancomycin resistance and multidrug resistance (IDDF2025-ABS-0200 figure 1. Multivariate Cox regression models for estimating one-year Clostridioides difficile infection (CDI) risk in rifaximin initiators compared to non-users).Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0200 Figure 1 Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0200 Figure 2 Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0200 Figure 3 Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0200 Figure 4 Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0200 Figure 5 Conclusions Rifaximin use is associated with a significantly increased risk of AMR and CDI in cirrhotic..."

Clinical • CNS Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatic Encephalopathy • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Liver Cirrhosis • Septic Shock

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Sadat City University | N=84 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Constipation • Gastroenterology • Gastrointestinal Disorder

Predict the risk of rifaximin treatment relapse based on clinical characteristics of patients with small intestinal bacterial overgrowth (IDDF 2025) - "Interpretability analysis results of the optimal prediction model for relapse as SIBO).View this table:View inline View popup Abstract IDDF2025-ABS-0184 Table 1 Baseline characteristics of studyDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0184 Figure 2 Sample characteristics distribution and correlation analysisDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0184 Figure 3 Network diagram of feature selected resultsDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0184 Figure 4 Model evaluation metrics before and after feature selectionDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0184 Figure 5 Interpretability analysis results of the optimal prediction model for relapse as SIBOConclusions Our study was the first to conduct a machine learning approach to predict relapse after rifaximin treatment for SIBO. We make a prediction model which can help clinicians to..."

Clinical

RESULTS OF A MULTICENTER STUDY ON THE IMPACT OF COMBINATION THERAPY WITH RIFAXIMIN AND TRIMEBUTINE ON QUALITY OF LIFE AND DISEASE COURSE IN UNCOMPLICATED DIVERTICULAR DISEASE IN REAL CLINICAL PRACTICE (ALLIANCE) (UEGW 2025) - No abstract available

Clinical • Combination therapy • HEOR • Gastrointestinal Disorder

New choice for small intestinal bacterial overgrowth: an RCT comparing berberine and rifaximin (IDDF 2025) - "Genus-level microbiota composition differed between responders, with BBR responders exhibiting higher baseline proportions of Phascolarctobacterium, Klebsiella, and Haemophilus, and lower Coprobacter. At Week 6, both groups showed enriched Bacteroides, while BBR responders had elevated Phascolarctobacterium, Streptococcus, and Haemophilus, with lower Bifidobacterium (IDDF2025-ABS-0189 figure 2(D) Treatment Response Outcomes and Their Associations with Patient Symptoms, Breath Test Parameters, and Gut Microbiota).Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0189 Figure 1 Study workflow and clinical outcomesDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0189 Figure 2 Treatment response outcomes and their associations with patient symptoms, breath test parameters, and gut microbiotaConclusions BBR is non-inferior to RIF for SIBO treatment and offers a promising and cost-effective new option."

The efficacy of rifaximin in preventing liver cirrhosis complications, including spontaneous bacterial peritonitis, encephalopathy, variceal bleeding, and all-cause mortality in adult patients with liver cirrhosis: a meta-analysis (IDDF 2025) - "Occurrence of Variceal Bleeding).Download figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0015 Figure 1 Recurrence of spontaneous bacterial peritonitisDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0015 Figure 2 Occurrence of hepatic encephalopathyDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0015 Figure 3 All-cause mortalityDownload figure Open in new tab Download powerpoint Abstract IDDF2025-ABS-0015 Figure 4 Occurrence of variceal bleedingConclusions Rifaximin demonstrates superior efficacy in preventing liver cirrhosis complications, including spontaneous bacterial peritonitis and hepatic encephalopathy, compared to the current standard of care, Norfloxacin. Additionally, Rifaximin exhibits a more favorable adverse effect profile and a reduced risk of antibiotic resistance."

Retrospective data • CNS Disorders • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis

POTENTIAL ROLE OF RIFAXIMIN IN MANAGING SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (UEGW 2025) - No abstract available

Clinical • Hepatology

NEW CHOICE FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: AN RCT COMPARING BERBERINE AND RIFAXIMIN (UEGW 2025) - No abstract available

RIFAXIMIN FOR SMALL INTESTINAL BACTERIAL OVERGROWTH. CAN WE PREDICT THE RESPONSE? (UEGW 2025) - No abstract available

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial. (PubMed, J Hepatol) - P3 | "RFX had no beneficial effect in terms of 12-month survival or incidence of complications of liver cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels. Improving patient adherence could reduce liver complications of cirrhosis."

Clinical • Journal • CNS Disorders • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatology • Immunology • Liver Cirrhosis • Nephrology • Renal Disease

Hepatic Encephalopathy Induced by Small Bowel Obstruction in a Patient With Primary Biliary Cholangitis. (PubMed, Cureus) - "The patient was managed conservatively with bowel decompression, and HE was successfully treated with rifaximin and, following the resolution of the obstruction, with lactulose. The patient made a good neurological recovery with normalization of biochemical markers and was discharged from the intensive care unit (ICU) in a stable condition. This case underscores the importance of recognizing and promptly addressing reversible precipitants of HE and illustrates the challenges of managing HE in the context of gastrointestinal obstruction."

Journal • CNS Disorders • Constipation • Critical care • Gastroenterology • Gastrointestinal Disorder • Hepatic Encephalopathy • Hepatology • Immunology • Liver Failure • Primary Biliary Cholangitis • Psychiatry

A CASE OF IATROGENIC SUBDURAL HEMATOMA AFTER BEGINNING LINEZOLID AND RIFAXIMIN STATUS POSTLUNG TRANSPLANT (CHEST 2025) - No abstract available

Clinical • CNS Disorders • Transplantation

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (clinicaltrials.gov) - P=N/A | N=174 | Recruiting | Sponsor: General Hospital of Shenyang Military Region | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Fibrosis • Gastroenterology • Hepatic Encephalopathy • Hepatology • Immunology • Liver Cirrhosis

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis (clinicaltrials.gov) - P2/3 | N=0 | Withdrawn | Sponsor: Wake Forest University Health Sciences | N=100 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cystic Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Pain • Pulmonary Disease • Respiratory Diseases

ARGO-HEC: A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. (clinicaltrials.gov) - P4 | N=252 | Completed | Sponsor: Qurratul Ain Jamil

New P4 trial • CNS Disorders • Hepatic Encephalopathy

development and hepatotoxicity of rifamycins Derivatives. (PubMed, Expert Opin Drug Metab Toxicol) - "Further research is needed to clarify the detailed mechanisms of rifamycin-induced liver injury. Mechanism-based strategies are also expected to prevent the toxicity of rifamycin derivatives."

Journal • Review • Hepatology • Infectious Disease • Liver Failure • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis. (PubMed, JAMA) - No abstract available

Journal • Fibrosis • Immunology

Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis. (PubMed, JAMA) - No abstract available

Journal • Fibrosis • Immunology

Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis. (PubMed, JAMA) - No abstract available

Journal • Fibrosis • Immunology

Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis. (PubMed, JAMA) - No abstract available

Journal • Fibrosis • Immunology

Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis-Reply. (PubMed, JAMA) - No abstract available

Journal • Fibrosis • Immunology

Rifaximin as a Therapeutic Ally in the Modulation of Dysbiosis: A Narrative Review of Its Applicability in Gastrointestinal Disorders. (PubMed, GE Port J Gastroenterol) - "Rifaximin, by targeting and modulating the microbiota, may serve as a powerful tool in the approach of these conditions. This narrative review summarizes the main uses of rifaximin in gastrointestinal disorders like irritable bowel syndrome, diverticular disease, small intestinal bacterial overgrowth, traveler's diarrhea, hepatic encephalopathy, Clostridioides difficile infection, and inflammatory bowel disease."

Journal • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hepatic Encephalopathy • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease

The effects of rifaximin and lactulose on the gut-liver-brain axis in rats with minimal hepatic encephalopathy. (PubMed, PLoS One) - "Rifaximin and lactulose may enhance cognitive performance in MHE rats by modulating gut microbiota metabolism and preserving the intestinal barrier integrity. This modulation is associated with lowered ammonia levels, decreased translocation of LPS to the liver, and reduced inflammatory response, both in the liver and systemically."

IO biomarker • Journal • Preclinical • CNS Disorders • Cognitive Disorders • Hepatic Encephalopathy • Oncology • IL1B • OCLN • TLR4 • TNFA

A Randomized Controlled Trial Of Antibiotics Targeting Adherent And Invasive Escherichia Coli (Aiec) Vs Placebo In Crohn's Disease: The Teorem Trial. (PubMed, J Crohns Colitis) - "A combination of ciprofloxacin and rifaximin was not superior to placebo to achieve endoscopic endpoints in patients with ileal CD colonized with AIEC."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Rifaximin Inhibits Small Bowel Angiodysplasia-Associated Angiogenesis by Attenuating LncRNA-HIF1A-AS2/miR-153-3p/HIF-1 α/Ang-2 Axis. (PubMed, Curr Med Sci) - "The lncRNA-HIF1A-AS2/miR-153-3p/HIF-1α/Ang-2 axis is critically involved in SBAD-associated angiogenesis. Rifaximin is a potential therapeutic option for SBAD via blockade of this axis."

Journal • Cardiovascular • HIF1A • HIF1A-AS2